11:36 AM EDT, 09/09/2024 (MT Newswires) -- CorMedix ( CRMD ) said Monday it has signed a multiyear contract with an unnamed healthcare company to supply DefenCath to its facilities in the US.

Shipments for DefenCath are expected to start in Q4, CorMedix ( CRMD ) said. DefenCath is indicated to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter.

CorMedix ( CRMD ) received approval of DefenCath under the Limited Population Pathway for Antibacterial and Antifungal Drugs in November last year, and began commercialization of the product in the inpatient setting in April.

Price: 5.49, Change: -0.27, Percent Change: -4.77